Search
North Carolina Paid Clinical Trials
A listing of 2618 clinical trials in North Carolina actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
1825 - 1836 of 2618
North Carolina is currently home to 2618 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Durham, Charlotte, Winston-Salem and Chapel Hill. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Trial
Type 2 Diabetes Clinical Trial
Recruiting
Can changing your breakfast improve your type 2 diabetes? If you have an HbA1C of 7.0% or higher, you are invited to participate in an online study at the University of Michigan.
Conditions:
Type 2 Diabetes
Diabetes Mellitus Type 2 in Obese
Diabetes Type Two
Type 2 Diabetes Mellitus
Diabete Type 2
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with CareGLP to offer trusted access to GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
Youth Partners in Care for Suicide Prevention
Recruiting
This randomized comparative effectiveness trial will compare two evidence-based approaches to emergency care for youth ages 13-24 who present to the Emergency Department (ED) with suicidal ideation or behavior. Outcomes will be monitored at baseline and at 3, 6 \& 12 month follow-up assessments.
Gender:
ALL
Ages:
Between 13 years and 24 years
Trial Updated:
12/09/2024
Locations: Duke University, Durham, North Carolina
Conditions: Suicide and Self-harm
Safety and Efficacy of Interferon-Gamma 1b in Patients With Candidemia
Recruiting
A multi-center open label adaptive randomized interventional phase 2 study to evaluate safety and efficacy of rIFN-y treatment in patiens with candidemia.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/09/2024
Locations: Duke University, Durham, North Carolina
Conditions: Candidemia
A Study With Eptinezumab in Adolescents (12-17 Years) With Chronic Migraine
Recruiting
To find out if eptinezumab is better than placebo (normal saline solution) in lowering the number of days with migraine in young people ages 12 to 17 with chronic migraine.
Gender:
ALL
Ages:
Between 12 years and 17 years
Trial Updated:
12/09/2024
Locations: OnSite Clinical Solutions, LLC - Randolph Rd - Charlotte - ClinEdge - PPDS, Charlotte, North Carolina
Conditions: Chronic Migraine in Children
Best Available Therapy Versus Autologous Hematopoetic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)
Recruiting
This is a multi-center prospective rater-masked (blinded) randomized controlled trial of 156 participants, comparing the treatment strategy of Autologous Hematopoietic Stem Cell Transplantation (AHSCT) to the treatment strategy of Best Available Therapy (BAT) for treatment-resistant relapsing multiple sclerosis (MS). Participants will be randomized at a 1 to 1 (1:1) ratio.
All participants will be followed for 72 months after randomization (Day 0, Visit 0).
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
12/09/2024
Locations: Duke University Medical Center, Durham, North Carolina
Conditions: Relapsing Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis
Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
Recruiting
This is a prospective, open-label, multi-cohort, non-randomized, multicenter phase 2 study evaluating LN-145 in patients with metastatic non-small-cell lung cancer
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
12/06/2024
Locations: University of North Carolina, Chapel Hill, North Carolina
Conditions: Metastatic Non Small Cell Lung Cancer
Brain Oxygen Optimization in Severe TBI, Phase 3
Recruiting
BOOST3 is a randomized clinical trial to determine the comparative effectiveness of two strategies for monitoring and treating patients with traumatic brain injury (TBI) in the intensive care unit (ICU). The study will determine the safety and efficacy of a strategy guided by treatment goals based on both intracranial pressure (ICP) and brain tissue oxygen (PbtO2) as compared to a strategy guided by treatment goals based on ICP monitoring alone. Both of these alternative strategies are used in s... Read More
Gender:
ALL
Ages:
14 years and above
Trial Updated:
12/06/2024
Locations: University of North Carolina Medical Center, Chapel Hill, North Carolina
Conditions: Brain Injuries, Traumatic
An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis Exposed to Ruxolitinib Cream Versus Topical Corticosteroids During Pregnancy: A US Claims Database Analysis
Recruiting
This study is to assess infant outcomes of women with AD who were exposed to ruxolitinib cream during pregnancy compared with a control cohort of women with AD who were exposed to a topical corticosteroid (TCS) during pregnancy.
Gender:
FEMALE
Ages:
14 years and above
Trial Updated:
12/05/2024
Locations: Syneos Health (remote site), Morrisville, North Carolina
Conditions: Pregnancy Related, Atopic Dermatitis
Study to Compare Maternal, Fetal, and Infant Outcomes of Women With Mild to Moderate Atopic Dermatitis Exposed to Ruxolitinib Cream During Pregnancy With an Unexposed Control Population
Recruiting
This observational (enrollment into the registry while the pregnancy is ongoing) study is being conducted to compare the frequency of major congenital malformation (MCM)s among infants of women exposed to ruxolitinib cream during pregnancy with infants of women not exposed to ruxolitinib cream during pregnancy.
Gender:
FEMALE
Ages:
Between 15 years and 50 years
Trial Updated:
12/05/2024
Locations: Syneos Health (remote site), Morrisville, North Carolina
Conditions: Pregnancy Related, Atopic Dermatitis
Phase 2b Trial Comparing HDV-Insulin Lispro to Insulin Lispro in Adults With Type 1 Diabetes Receiving Insulin Degludec
Recruiting
The goal of this study is to see if directing insulin to the liver will improve the low blood sugar that sometimes happens when injecting insulin in Type 1 diabetes patients. Participants will use continuous glucose monitoring to measure the sugar levels in their blood, and work with the doctor to find the best doses. One group of patients will get the liver targeting insulin, and the other group will use insulin they normally use for treating Type 1 diabetes. The participant will be part of the... Read More
Gender:
ALL
Ages:
Between 18 years and 79 years
Trial Updated:
12/05/2024
Locations: Asheville Clinical Research, Asheville, North Carolina
Conditions: Diabetes Mellitus, Type 1
Observational Study for Patients at Risk for Chronic Graft-Versus-Host Disease
Recruiting
The purpose of this prospective observational study is to collect data from participants who have recently had an allogenic Stem Cell Transplant(alloSCT) and are at risk of Chronic Graft Versus Host Disease(cGVHD)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/05/2024
Locations: University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
Conditions: cGVHD
US National OCS Heart Perfusion (OHP) Registry
Recruiting
This Registry is a sponsor initiated, multi-center, observational post-approval registry with independent academic oversight.
Gender:
ALL
Ages:
All
Trial Updated:
12/05/2024
Locations: University of North Carolina, Chapel Hill, North Carolina
Conditions: Heart Transplant
(Peak) a Phase 3 Randomized Trial of CGT9486+Sunitinib Vs. Sunitinib in Subjects with Gastrointestinal Stromal Tumors
Recruiting
This is a Phase 3, open-label, international, multicenter study of CGT9486 in combination with sunitinib. This is a multi-part study that will enroll approximately 442 patients. Part 1 consists of two evaluations: 1) confirming the dose of an updated formulation of CGT9486 to be used in subsequent parts in approximately 20 patients who have received at least one prior line of therapy for GIST and 2) evaluating the potential for drug-drug interactions between CGT9486 and sunitinib in approximatel... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/05/2024
Locations: Duke University, Durham, North Carolina
Conditions: Advanced Gastrointestinal Stromal Tumors, Metastatic Cancer